|
gptkbp:instanceOf
|
biotechnology company
|
|
gptkbp:acquisition
|
gptkb:AstraZeneca
gptkb:Portola_Pharmaceuticals
gptkb:Syntimmune
December 2020
|
|
gptkbp:CEO
|
gptkb:David_Brennan
|
|
gptkbp:clinicalTrials
|
Phase 1 trials for ALXN1720
Phase 2 trials for ALXN1210
Phase 3 trials for eculizumab
|
|
gptkbp:employees
|
approximately 3,000
|
|
gptkbp:focusArea
|
rare diseases
|
|
gptkbp:foundedBy
|
gptkb:Leonard_Bell
|
|
gptkbp:foundedIn
|
1992
|
|
gptkbp:headCoach
|
3,000+
|
|
gptkbp:headquarters
|
gptkb:Cambridge,_Massachusetts
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ALXN
|
|
gptkbp:keyPeople
|
gptkb:David_Hallal
Luca Santarelli
Megan McGowan
|
|
gptkbp:market
|
$30 billion (2021)
|
|
gptkbp:notableEvent
|
Soliris
Ultomiris
|
|
gptkbp:partnerships
|
gptkb:Bristol-Myers_Squibb
AbbVie
|
|
gptkbp:research_areas
|
neurology
hematology
infectious diseases
immunology
|
|
gptkbp:researchFocus
|
genetic disorders
metabolic disorders
autoimmune diseases
complement inhibition
transplantation
immune-mediated diseases
|
|
gptkbp:revenue
|
$1.5 billion (2020)
|
|
gptkbp:stockSymbol
|
gptkb:ALXN
|
|
gptkbp:subsidiary
|
Alexion_Pharmaceuticals,_Inc.
|
|
gptkbp:tradedOn
|
gptkb:NASDAQ
|
|
gptkbp:website
|
www.alexion.com
|